Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

Clicks: 364
ID: 114673
1997
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in an open label study in 37 frail institutionalized persons over age 65. Vaccination was well tolerated without significant side-effects. Thirty-six of 37 volunteers completed th …
Reference Key
ar1997vaccinesafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Falsey AR;Walsh EE;;
Journal Vaccine
Year 1997
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9269057
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine safety research support non-u.s. gov't female male aged 80 and over Antibodies viral / blood neutralization tests respiratory syncytial virus infections / immunology respiratory syncytial virus infections / prevention & control* viral fusion proteins / immunology vaccines immunoglobulin g / blood chronic disease human / immunology* respiratory syncytial virus viral vaccines / adverse effects respiratory tract infections / immunology a r falsey e e walsh pmid:9269057 doi:10.1016/s0264-410x(97)00002-9 homes for the aged nursing homes respiratory tract infections / prevention & control* synthetic / pharmacology* viral vaccines / pharmacology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.